Journal
NEUROTOXICOLOGY
Volume 25, Issue 1-2, Pages 271-277Publisher
ELSEVIER
DOI: 10.1016/S0161-813X(03)00106-2
Keywords
Alzheimer's disease; monoamine oxidase-B; deprenyl; rasagiline; lazabemide
Categories
Ask authors/readers for more resources
Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD. (C) 2003 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available